These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23921293)

  • 1. Ticagrelor-associated bleeding in a patient undergoing surgery for acute type A aortic dissection.
    Dalén M; Ivert T; Lindvall G; van der Linden J
    J Cardiothorac Vasc Anesth; 2013 Oct; 27(5):e55-7. PubMed ID: 23921293
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
    Kirkby NS; Leadbeater PD; Chan MV; Nylander S; Mitchell JA; Warner TD
    J Thromb Haemost; 2011 Oct; 9(10):2103-5. PubMed ID: 21812912
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
    Vaduganathan M; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress in platelet blockers: the target is the P2Y12 receptor.
    Patel PA; Lane B; Augoustides JG
    J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of platelet P2Y12 receptor inhibitors: fact or fiction?
    Moulias A; Xanthopoulou I; Alexopoulos D
    Curr Pharm Des; 2014; 20(28):4597-604. PubMed ID: 24730531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
    Cattaneo GJ; Podda GM; Cattaneo M
    Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
    Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
    Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
    Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor to prevent restenosis: new drug for an old hypothesis?
    Cayla G; Montalescot G; Collet JP
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2320-2. PubMed ID: 21084699
    [No Abstract]   [Full Text] [Related]  

  • 10. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
    Collet JP; O'Connor S
    Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ticagrelor on endothelial calcium signalling and barrier function.
    Gündüz D; Tanislav C; Schlüter KD; Schulz R; Hamm C; Aslam M
    Thromb Haemost; 2017 Jan; 117(2):371-381. PubMed ID: 27904901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
    Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
    Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of the P2Y12 antagonist ticagrelor on neointimal hyperplasia in a rabbit carotid anastomosis model†.
    Sürer S; Toktas F; Ay D; Eris C; Yavuz S; Turk T; Vural AH; Goncu MT; Gul NY; Yalcınkaya U
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):198-204. PubMed ID: 24876217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pharmacodynamics of Switching Between P2Y12 Receptor Antagonists.
    Price MJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1099-101. PubMed ID: 27282596
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
    Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.